A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

For many struggling with weight management, new medications like Wegovy, Mounjaro, and Saxenda have been seen as ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...